Fig. 1.

A transposon mutagenesis screen in EGFR-mutant PC9 lung adenocarcinoma cells for resistance to afatinib. (A) Flowchart representing the overall design of the screen. (B) Lysates from PC9 cells, YES1 clones, and MET clones treated with or without 500 nM afatinib for 60 min were subjected to immunoblot analysis with antibodies against the indicated proteins. (C) Lysates from PC9 cells and YES1 clones treated with 500 nM afatinib for 60 min were hybridized to human phosphokinase antibody arrays (ARY003B; R&D Systems).